Related Experiment Videos
The selenium and vitamin E cancer prevention trial
Eric A Klein1, Scott M Lippman, Ian M Thompson
1Section of Urologic Oncology, Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, OH 44195, Cleveland, USA. kleine@ccf.org
World Journal of Urology
|May 21, 2003
Summary
This study investigated if selenium and vitamin E prevent prostate cancer. Results are pending, but preclinical data suggest potential benefits for these supplements in cancer prevention.
Area of Science:
- Oncology
- Nutritional Science
- Preventive Medicine
Background:
- Emerging evidence suggests selenium and vitamin E may lower prostate cancer risk.
- The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was initiated to investigate this hypothesis.
Purpose of the Study:
- To determine if selenium and vitamin E, individually or combined, reduce prostate cancer incidence in healthy men.
Main Methods:
- A randomized, prospective, double-blind, placebo-controlled trial.
- The study employed a 2x2 factorial design.
- Enrollment targeted 32,400 men with normal digital rectal exam and prostate-specific antigen (PSA) levels ≤4 ng/ml.
Main Results:
- Preclinical and epidemiological data indicate potential chemopreventive efficacy of selenium and vitamin E for prostate cancer.
- Phase III trial data also suggest potential benefits.
Conclusions:
- SELECT represents a significant large-scale endeavor in prostate cancer chemoprevention research.
- The study commenced enrollment in 2001, with final results expected in 2013.